Abstract
Imaging plays an important role in early detection and staging of medullary thyroid carcinoma (MTC) as well as in follow-up to localize early recurrence. MTC is a rare, calcitonin-secreting thyroid malignancy often diagnosed by ultrasound and calcitonin screening as part of the routine workup for any thyroid nodule. If calcitonin is elevated, imaging studies are needed for preoperative staging, which dictates surgical management. This can be done by ultrasound of the neck and abdomen. Computed tomography (CT) or magnetic resonance imaging (MRI) studies for more distant disease are done preoperatively if calcitonin levels are higher than 500 pg/ml. Neither FDG-PET/CT nor F-DOPA-PET/CT are used routinely for preoperative staging but may contribute in doubtful individual cases. Postoperative elevated calcitonin is related to persistence or recurrence of MTC. Imaging studies to localize tumor tissue during postoperative follow-up include ultrasound, CT, MRI as well as PET studies. They should be used wisely, however, since treatment consequences are often limited, and even patients with persistent disease may survive long enough to accumulate significant radiation doses. Imaging studies are also useful for diagnosis of associated components of the hereditary MTC such as pheochromocytoma and primary hyperparathyroidism (pHPT).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- MTC:
-
Medullary thyroid carcinoma
- CTN:
-
Calcitonin
- US:
-
Ultrasound
- MRI:
-
Magnetic resonance imaging
- CT:
-
Computed tomography
- PET:
-
Positron emission tomography
References
Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH et al (2008) Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 32(7):1552–1558
American Thyroid Association Guidelines Task F, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid Official J Am Thyroid Assoc 19(6):565–612
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P et al (1996) Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med Official Publ Soc Nucl Med 37(6):912–916
Behr TM, Behe MP (2002) Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 32(2):97–109
Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A et al (1997) Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer 80(12):2436–2457
Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH et al (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 237(1):123–131
Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M et al (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19(1):65–71
Cantisani V, Grazhdani H, Fioravanti C, Rosignuolo M, Calliada F, Messineo D et al (2014) Liver metastases: contrast-enhanced ultrasound compared with computed tomography and magnetic resonance. World J Gastroenterol WJG 20(29):9998–10007
Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E et al (2008) MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Quar J Nucl Med Mol Imaging Official Publ Ital Assoc Nucl Med 52(4):430–440
Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y (2012) (1)(8)F-FDG-PET and (1)(8)F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol 56(2):136–142
Choi N, Moon WJ, Lee JH, Baek JH, Kim DW, Park SW (2011) Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. Acta Radiol 52(3):312–316
Clarke SE, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med Official Publ Soc Nucl Med 29(1):33–38
de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11(8):786–794
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
Foschini MP, Ragazzi M, Parmeggiani AL, Righi A, Flamminio F, Meringolo D et al (2007) Comparison between echo-color doppler sonography features and angioarchitecture of thyroid nodules. Int J Surg Pathol 15(2):135–142
Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F (1995) Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 42(1):31–37
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L et al (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185–4190
Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K (2003) Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88(2):637–641
Guerin C, Lowery A, Gabriel S, Castinetti F, Philippon M, Vaillant-Lombard J et al (2015) Preoperative imaging for focused parathyroidectomy: making a good strategy even better. Eur J Endocrinol Eur Fed Endocr Soc 172(5):519–526
Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28(1):64–71
Ilias I, Pacak K (2004) Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 1018:495–504
Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14(3):587–599
Jacques AE, Sahdev A, Sandrasagara M, Goldstein R, Berney D, Rockall AG et al (2008) Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 18(12):2885–2892
Kim SH, Kim BS, Jung SL, Lee JW, Yang PS, Kang BJ et al (2009) Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol Official J Korean Radiol Soc 10(2):101–105
Koopmans KP, de Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ et al (2008) 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med Official Publ Soc Nucl Med 49(4):524–531
Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R et al (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134(6):946–54 (discussion 54–5)
Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M (2007) Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid Official J Am Thyroid Assoc 17(7):635–638
Leclere J, Sidibe S, Lassau N, Gardet P, Caillou B, Schlumberger M et al (1996) Ultrasonographic aspects of hepatic metastases of thyroid medullary cancers. J Radiol 77(2):99–103
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H et al (2010) Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid Official J Am Thyroid Assoc 20(5):527–533
Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655–2663
Machens A, Lorenz K, Dralle H (2013) Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J Clin Endocrinol Metab 98(2):E336–E345
Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L et al (2005) High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90(2):779–788
Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gonen M et al (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med Official Publ Soc Nucl Med 48(4):501–507
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C et al (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92(12):4590–4597
Quayle FJ, Fialkowski EA, Benveniste R, Moley JF (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142(6):800–5 (discussion 5 e1)
Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A et al (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238(4):369–373
Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S et al (2008) The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol J Eur Soc Surg Oncology Br Assoc Surg Oncol 34(5):581–586
Santhanam P, Taieb D (2014) Role of (18) F-FDOPA PET/CT imaging in endocrinology. Clin Endocrinol 81(6):789–798
Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A et al (2012) Comparison of 18F-DOPA, 18F-FDG and 68 Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 39(4):569–580
Triggiani V, Guastamacchia E, Licchelli B, Tafaro E (2008) Microcalcifications and psammoma bodies in thyroid tumors. Thyroid Official J Am Thyroid Assoc 18(9):1017–1018
Troncone L, Rufini V, Maussier ML, Valenza V, Daidone MS, Luzi S et al (1991) The role of [131I]metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: results in five cases. J Nucl Biol Med 35(4):327–331
Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC et al (2012) Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med Official Publ Soc Nucl Med 53(12):1863–1871
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF et al (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association
Wolinski K, Rewaj-Losyk M, Ruchala M (2014) Sonographic features of medullary thyroid carcinomas–a systematic review and meta-analysis. Endokrynologia Polska 65(4):314–318
Zhang B, Jiang YX, Liu JB, Yang M, Dai Q, Zhu QL et al (2010) Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid Official J Am Thyroid Assoc 20(1):51–57
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Delorme, S., Raue, F. (2015). Medullary Thyroid Carcinoma: Imaging. In: Raue, F. (eds) Medullary Thyroid Carcinoma. Recent Results in Cancer Research, vol 204. Springer, Cham. https://doi.org/10.1007/978-3-319-22542-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-22542-5_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22541-8
Online ISBN: 978-3-319-22542-5
eBook Packages: MedicineMedicine (R0)